KEYNOTE 050 trial: what clinicians have said so far
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
- NCT02511184 ↗
- Terminated
- Pfizer
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on KEYNOTE 050 (crizotinib plus pembrolizumab in untreated ALK-positive advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE 050 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A PHASE 1B STUDY OF CRIZOTINIB IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH UNTREATED ADVANCED ALK-TRANSLOCATED NON SMALL CELL LUNG CANCER
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- ALK-positive Advanced NSCLC
- Interventions
- Crizotinib; Pembrolizumab
- Arms
- Dose finding and dose expansion phases · Experimental
- Enrollment
- 9
- Primary outcomes
- Number of Participants With Dose-limiting Toxicity (DLT)
- Sponsor
- Pfizer with Merck Sharp & Dohme LLC
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Results posted
- Yes
- Registry record
- NCT02511184 · updated Jul 1, 2019